+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 2Years - 60Years
All Genders
ID06447025

Long-Term Open-Label Study of Subcutaneous CTI-1601 Safety and Effects in Friedreichs Ataxia Patients

Led by Larimar Therapeutics, Inc. · Updated on 2026-10-27

85

Participants Needed

10

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying Friedreichs ataxia FRDA, a condition affecting children aged 2 years and older, adolescents, and adults up to 60 years old. This open-label study evaluates the long-term safety, tolerability, pharmacokinetics PK, pharmacodynamics PD, and clinical effects of CTI-1601, a recombinant fusion protein designed to deliver the deficient human frataxin protein in FRDA patients. The study enrolls both patients who have and have not participated in prior CTI-1601 trials. Participants receive daily subcutaneous injections of CTI-1601. Those aged 18 years and older receive a fixed dose of 50 mg, while children and adolescents aged 2 to 17 years receive a weight-based dose of 0.8 mgkg up to a maximum of 50 mg. The treatment period lasts up to 24 months, during which safety, clinical, and biological effects are monitored closely. During the study, participants undergo regular assessments including monitoring of adverse events, heart function via electrocardiograms and echocardiograms, and neurological and motor function tests such as the modified Friedreichs Ataxia Rating Scale mFARS, 9-hole peg test, and timed 25-foot walk. Tissue frataxin levels are measured through cheek swabs and skin biopsies. Patient and clinician global impressions of change, activities of daily living, fatigue, and gene expression are also evaluated. Pharmacokinetic sampling occurs at multiple time points throughout the study to analyze drug exposure. The study lasts up to 24 months, with ongoing safety and clinical monitoring.

CONDITIONS

Brief Title

An Open-Label Study of CTI-1601 in Subjects With Friedreich's Ataxia

Research Team

L

Larimar Therapeutics, Inc.

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here